share_log

藥明康德：中期報告2024

WUXI APPTEC: Interim Report 2024

HKEX ·  Sep 4, 2024 09:00

Summary by Moomoo AI

無錫藥明康德於2024年中期報告中公佈，公司實現營業收入人民幣17,240.9百萬元，同比減少8.6%；實現歸母淨利潤人民幣4,239.8百萬元，同比減少20.2%。公司為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，並在亞洲、歐洲、北美等地設有運營基地。2024年上半年，公司新增客戶超過500家，全球客戶對公司服務的需求持續增長。截至2024年6月末，公司在手訂單人民幣431.0億元，剔除新冠商業化項目同比增長33.2%。報告期內，公司繼續投資能力和規模建設，預計2024年收入可達到人民幣383–405億元，剔除新冠商業化項目後將保持正增長。
無錫藥明康德於2024年中期報告中公佈，公司實現營業收入人民幣17,240.9百萬元，同比減少8.6%；實現歸母淨利潤人民幣4,239.8百萬元，同比減少20.2%。公司為全球醫藥及生命科學行業提供一體化、端到端的新藥研發和生產服務，並在亞洲、歐洲、北美等地設有運營基地。2024年上半年，公司新增客戶超過500家，全球客戶對公司服務的需求持續增長。截至2024年6月末，公司在手訂單人民幣431.0億元，剔除新冠商業化項目同比增長33.2%。報告期內，公司繼續投資能力和規模建設，預計2024年收入可達到人民幣383–405億元，剔除新冠商業化項目後將保持正增長。
Wuxi Apptec announced in its mid-2024 report that the company achieved a revenue of RMB 1,724.09 million, a year-on-year decrease of 8.6%; realized a net profit attributable to the parent company of RMB 423.98 million, a year-on-year decrease of 20.2%. The company provides integrated, end-to-end new drug research and production services to the global pharmaceutical and life sciences industry, with operational bases in Asia, Europe, and North America. In the first half of 2024, the company added more than 500 new customers, and the global demand for the company's services continues to grow. As of the end of June 2024, the company's backlog of orders amounted to RMB 43.1 billion, a year-on-year increase of 33.2% excluding the COVID-19 commercialization project. During the reporting period, the company continued to invest in its capabilities and scale, and it is expected that the revenue in 2024 will reach RMB 38.3-40.5 billion, with positive growth excluding the COVID-19 commercialization project.
Wuxi Apptec announced in its mid-2024 report that the company achieved a revenue of RMB 1,724.09 million, a year-on-year decrease of 8.6%; realized a net profit attributable to the parent company of RMB 423.98 million, a year-on-year decrease of 20.2%. The company provides integrated, end-to-end new drug research and production services to the global pharmaceutical and life sciences industry, with operational bases in Asia, Europe, and North America. In the first half of 2024, the company added more than 500 new customers, and the global demand for the company's services continues to grow. As of the end of June 2024, the company's backlog of orders amounted to RMB 43.1 billion, a year-on-year increase of 33.2% excluding the COVID-19 commercialization project. During the reporting period, the company continued to invest in its capabilities and scale, and it is expected that the revenue in 2024 will reach RMB 38.3-40.5 billion, with positive growth excluding the COVID-19 commercialization project.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 301

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
KING INTL INV
00928
0.030
BIOCYTOGEN-B
02315
9.190
MABPHARM-B
02181
0.330
TYK MEDICINES-B
02410
32.350
CT ENTERPRISE
03839
1.620
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More
Can Big Tech earnings ignite the markets again?
85%
15%
Yes
No
5168 votes
AMZN earnings preview: Grab rewards by guessing the opening price!
Hi mooers!
With the development of e-commerce and cloud computing, $Amazon (AMZN.US)$ has attracted widespread market attention. It is releasing its last quarter earnings on February 6th after bell.
Unlock insights with AMZN Earnings Hub>>
Rewards
● An equal share of 5,000 points: For mooers who correctly guess the winner who makes the biggest %gains in intraday trading on the first day after their earnings (e.g., If 50 mooers ma...

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK